Abivax slides 5% as takeover-fueled rally fades ahead of late-Q2 Phase 3 readout
Abivax ADS (ABVX) fell 5.05% to $104.06 as investors cooled on recent takeover buzz that had lifted the stock earlier in March. With no new company-specific catalyst disclosed on March 27, trading looked driven by profit-taking ahead of late Q2 2026 Phase 3 maintenance topline results for obefazimod in ulcerative colitis.
1. What’s moving the stock
Abivax’s U.S.-listed ADS fell about 5% in Friday trading, a pullback that appears tied to fading M&A momentum rather than a fresh fundamental update. Earlier in March, the stock jumped on renewed takeover speculation tied to reported due-diligence access for AstraZeneca, but no confirmed offer emerged, leaving shares vulnerable to profit-taking as the rumor premium cooled. (sahmcapital.com)
2. The fundamental backdrop investors are keying on
The company’s latest disclosed operational update reiterated that its pivotal ABTECT Phase 3 maintenance trial for obefazimod in moderate-to-severe ulcerative colitis is still expected to report topline results in late Q2 2026, a binary event that can amplify volatility as positioning shifts. Abivax also disclosed a March 18, 2026 DSMB safety review that found no new safety signals, supporting continued trial execution but not adding a new near-term catalyst for March 27 trading. (globenewswire.com)
3. Balance sheet and positioning into the next catalyst
Abivax ended 2025 with €530.4 million of cash, cash equivalents and short-term investments and projected runway into Q4 2027, meaning the near-term story is less about funding risk and more about clinical-readout and strategic-option value. That setup can lead to sharp, headline-sensitive moves as traders handicap the timing of the Phase 3 maintenance data and the probability that a strategic buyer returns after the readout. (globenewswire.com)